Equine BNP antibody and antigen (recombinant protein)
Diagnostic anti-Equine BNP antibodies pairs and antigen for animal health (animal Equine/Horse Cardiovascular Disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Equine disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-BNP-Ag01 | Equine BNP | $3090.00 |
GMP-EQU-BNP-Ab01 | Anti-Equine BNP mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-BNP-Ab02 | Anti-Equine BNP mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-BNP-Ab03 | Anti-Equine BNP human monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-BNP-Ab04 | Anti-Equine BNP human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-EQU-BNP-Ag01 |
Product Name | Equine BNP |
Target/Biomarker | Equine BNP |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine BNP antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in BNP level test of animal Equine/Horse with Cardiovascular Disease. |
Tag | His | Reconized/Reactive Specics | Equine BNP |
Product description | Recombinant Equine BNP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-BNP-Ab01,GMP-EQU-BNP-Ab02 |
Target/Biomarker | Equine BNP |
Product Name | Anti-Equine BNP mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine BNP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine BNP antibodies in Equine BNP level test of animal Equine/Horse with Cardiovascular Disease. |
Product description | Anti-Equine BNP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine BNP antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-BNP-Ab03,GMP-EQU-BNP-Ab04 |
Target/Biomarker | Equine BNP |
Product Name | Anti-Equine BNP human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Equine BNP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine BNP antibodies in Equine BNP level test of animal Equine/Horse with Cardiovascular Disease. |
Product description | Anti-Equine BNP mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Equine B-type Natriuretic Peptide, or Equine BNP, is a remarkable peptide hormone that forms an integral part of the cardiovascular system in horses (Equus ferus caballus). It belongs to a family of natriuretic peptides, which are substances with profound effects on blood pressure regulation, fluid balance, and overall cardiovascular homeostasis. In the equine context, BNP is particularly noteworthy for its role in responding to cardiac stress and maintaining hemodynamic equilibrium.
Structurally, Equine BNP is comprised of a sequence of amino acids, and upon release into the bloodstream, it can be enzymatically cleaved to produce an active form known as BNP-32. This active form carries out its physiological functions by binding to specific receptors in various tissues, particularly in the kidneys and blood vessels.
The primary source of Equine BNP synthesis is the cardiac muscle itself, specifically the ventricular cardiomyocytes. When the heart faces increased pressure or stretch, a common occurrence during certain cardiac pathologies or conditions that demand increased cardiac output (e.g., exercise), these cells respond by secreting Equine BNP into the circulation.
The actions of Equine BNP are remarkable and have a profound impact on cardiovascular physiology. One of its main effects is vasodilation, which means it causes the blood vessels to relax and widen. This vasodilatory effect reduces peripheral vascular resistance, resulting in decreased afterload on the heart. Additionally, Equine BNP promotes diuresis, which means it enhances urine production. By increasing urine output, Equine BNP helps to eliminate excess fluid from the body, reducing blood volume and further alleviating the heart's workload.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.